The short answer
- Medtech buyers — procurement leads, clinical advisors, health-system consultants — increasingly use AI as a first filter to build vendor shortlists, before any sales conversation.
- The cycle is long and compliance-sensitive, so the AI narrative about you has more time to shape the decision — and a wrong or absent one does more damage than in a faster market.
- Misclassification is the specific medtech danger: being described as a general manufacturer rather than a specialist device maker puts you in front of the wrong buyers.
- Because procurement is evidence-led, the independent sources AI trusts matter even more here than in most sectors.
Ireland's medical-device sector is globally significant, and its buyers are among the most careful in any market. Procurement leads, clinical advisors and health-system consultants research suppliers rigorously before any conversation begins — and increasingly, the first filter in that research is an AI tool. For a medtech company, what AI says about you is now part of the procurement process whether you manage it or not.
How medtech buyers research now
The decision is evidence-led, regulated and cautious — but the starting point has shifted. A procurement lead or clinical advisor will often open with a question to an AI tool: who makes this type of device, what are the specialist suppliers for this procedure, what are the alternatives to an incumbent. The shortlist begins forming there, long before any RFI or tender. If you are not named, or named in the wrong terms, you are filtered out before the formal process even starts.
Why the stakes are higher in medtech than almost anywhere
- The cycle is long, so a wrong narrative compounds. A stale or inaccurate AI description does not brief one buyer once; it briefs a series of stakeholders over months, each forming an impression before you engage.
- It is compliance-sensitive, so accuracy is not optional. An AI tool repeating an out-of-date regulatory status, the wrong indications, or a discontinued product line is not merely unhelpful in this sector — it can be disqualifying.
- Several stakeholders research independently. Procurement, clinical and technical reviewers may each consult AI. A consistent, correct narrative reinforces you across all of them; an inconsistent one fragments your case.
The specific medtech failure: misclassification
The most common and most damaging pattern we see in medtech is not absence — it is being placed in the wrong category. A specialist device manufacturer described by AI as a general engineering firm is, for a procurement filter, effectively invisible to the right buyer. The company is present, fluent, even well-described — just filed under a heading no clinical buyer would search. In device procurement, that miscategorisation does as much damage as being missing altogether.
In medtech the sales cycle is long enough for a wrong AI description to brief every stakeholder before you ever get to speak.
Why your own website will not save you here
Medtech procurement trusts independent corroboration above self-description: regulatory listings, registries, clinical and industry references, distributor directories. AI weighs these heavily. If they are thin, outdated, or describe an older portfolio, AI's view of you lags your actual capability — and updating your own site does not move them. The sources that shape the answer sit largely outside your domain, which is precisely why the gap is so easy to miss.
The Ireland advantage
Because Ireland's medtech cluster is so concentrated, buyers and consultants researching Irish suppliers lean on a definable set of openly-readable sources and bodies. Knowing which of those AI actually draws on for a given device category makes the diagnosis sharper and the fixes more precise than a generic, market-agnostic review could be.
What to do
The practical first step is to see what AI says when a procurement lead or clinical advisor asks about your device category — in the right category, accurately, against the competitors you actually face. That is a diagnosis, not a dashboard reading, and in a sector this evidence-led it is the most useful half-hour you can spend.